Description

The recombinant humanized anti-CD28 monoclonal antibody is a functional IgG2b-type antibody produced via hybridoma cell line, engineered to bind with high affinity to the extracellular IgV-like domain of CD28 on T cells. By mimicking the natural CD28-B7 interaction, it activates the PI3K-Akt-mTOR and NF-κB signaling pathways, synergizing with CD3 antibody-mediated TCR priming to achieve complete T-cell activation.

In ex vivo T-cell expansion systems, this antibody significantly enhances clonal expansion efficiency, promotes central memory T-cell (Tcm) differentiation, and suppresses activation-induced cell death (AICD).

For NK cell culture applications, it potentiates ADCC efficacy and IFN-γ secretion in CD28+ NK subsets through cross-activation, while synergizing with IL-15 to optimize metabolic reprogramming.

Manufactured using animal component-free media and chromatographic purification, the product ensures compliance with release specifications through stringent controls on host DNA residuals, host protein residuals, and ultra-low endotoxin levels.

It is applicable for the development of CAR-T, TIL, and bispecific antibody-engaged NK cell therapies.

Specifications

Test Item	Specification	Results
Appearance	Should be a colorless and transparent liquid	Compliance
Identity	The electrophoretic bands should be consistent with the molecular weight of the product	Compliance
Visible Particle	Should be no visible particle	Compliance
pH	6.5 – 7.5	7.3
Concentration	1.0 – 1.5 mg/mL	1.0 mg/mL
Purity	>95.0%	>95.0%
Endotoxin	<0.01 EU/μg	<0.01 EU/μg
Mycoplasma	Should be negative	Negative
Sterility	No growth	No growth
Biological Activity	Binding rate with Jurkat cells >90%	96%

Features

Engineered recombinant humanized anti-CD28 monoclonal antibody with high specificity for the extracellular IgV-like domain of human CD28, facilitating robust co-stimulatory signaling in T cells.
Mimics physiological CD28–B7 interaction to activate key intracellular pathways including PI3K-Akt-mTOR and NF-κB, synergizing with TCR engagement for complete T-cell activation.
Promotes efficient ex vivo T-cell expansion, enhances central memory T-cell differentiation, and reduces activation-induced cell death (AICD) for improved culture outcomes.
Potentiates functional responses in CD28⁺ NK cell subsets, augmenting ADCC and IFN-γ secretion, and synergizes with IL-15 to support metabolic reprogramming.
Manufactured in animal component-free media with chromatographic purification to ensure low host residue levels and ultra-low endotoxin, meeting stringent quality criteria.
Ideal for use in cell therapy research, including CAR-T, TIL, and bispecific engager-driven immunotherapy development.

Applications

Ex vivo T-cell activation and expansion

Ex vivo T-cell activation and expansion in research and cell therapy development.

Central memory T-cell (Tcm) differentiation

Enhancing central memory T-cell (Tcm) differentiation in culture systems.

CD28-expressing NK cell subsets

Augmenting functional NK cell responses in CD28-expressing NK cell subsets.

CAR-T cell platforms

Supporting development and validation of CAR-T cell platforms.

TIL expansion and optimization

Facilitating TIL expansion and optimization of antitumor reactivity.

Bispecific antibodies and immune engager systems

Enabling studies involving bispecific antibodies and immune engager systems.

Storage

Stable for up to 24 months when stored at 2-8°C under sterile condition.

Documents

📄 Data Sheet 📄 SDS 📄 COA

Attention

For research and manufacturing purposes only.

Anti-Human CD28 Monoclonal Antibody (CD28 Mab)